OTCMKTS:CTDH

Cyclo Therapeutics Stock Forecast, Price & News

$10.20
-0.05 (-0.49 %)
(As of 06/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.00
$10.85
50-Day Range
$6.75
$10.81
52-Week Range
$0.03
$0.35
Volume383,377 shs
Average Volume245,004 shs
Market Capitalization$1.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.89
30 days | 90 days | 365 days | Advanced Chart
Receive CTDH News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.42 out of 5 stars

Medical Sector

1797th out of 2,102 stocks

Industrial Organic Chemicals Industry

32nd out of 40 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Cyclo Therapeutics (OTCMKTS:CTDH) Frequently Asked Questions

What stocks does MarketBeat like better than Cyclo Therapeutics?

Wall Street analysts have given Cyclo Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cyclo Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Cyclo Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Cyclo Therapeutics' stock was trading at $0.1155 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTDH stock has increased by 8,731.2% and is now trading at $10.20.
View which stocks have been most impacted by COVID-19
.

Who are Cyclo Therapeutics' key executives?

Cyclo Therapeutics' management team includes the following people:
  • Mr. N. Scott Fine, Chief Exec. Officer (Age 63, Pay $479.58k)
  • Dr. Jeffrey L. Tate, COO, Chief Quality Officer & Director (Age 62, Pay $252.93k)
  • Dr. Sharon H. Hrynkow, Chief Scientific Officer, Sr. VP of Medical Affairs & Member of Scientific Advisory Board (Age 60, Pay $337.08k)
  • Mr. Joshua M. Fine, CFO & Sec. (Age 38)
  • Mr. George L. Fails, Exec. VP and Operations Mang. (Age 75)
  • Mr. Michael Eric Lisjak, Chief Regulatory Officer & Sr. VP for Bus. Devel.

Who are some of Cyclo Therapeutics' key competitors?

What other stocks do shareholders of Cyclo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclo Therapeutics investors own include Roku (ROKU), Advanced Micro Devices (AMD), Heat Biologics (HTBX), AT&T (T), American Airlines Group (AAL), Aurora Cannabis (ACB), Albemarle (ALB), Yamana Gold (AUY), Alteryx (AYX) and (CGC).

What is Cyclo Therapeutics' stock symbol?

Cyclo Therapeutics trades on the OTCMKTS under the ticker symbol "CTDH."

How do I buy shares of Cyclo Therapeutics?

Shares of CTDH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclo Therapeutics' stock price today?

One share of CTDH stock can currently be purchased for approximately $10.20.

How much money does Cyclo Therapeutics make?

Cyclo Therapeutics has a market capitalization of $1.73 billion and generates $1.01 million in revenue each year.

How many employees does Cyclo Therapeutics have?

Cyclo Therapeutics employs 5 workers across the globe.

What is Cyclo Therapeutics' official website?

The official website for Cyclo Therapeutics is www.ctd-holdings.com.

Where are Cyclo Therapeutics' headquarters?

Cyclo Therapeutics is headquartered at 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653.

How can I contact Cyclo Therapeutics?

Cyclo Therapeutics' mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The biotechnology company can be reached via phone at 386-418-8060 or via email at [email protected]


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.